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Purpose: Many patients with benign prostatic hyperplasia (BPH) have storage symptoms. The aim of this study was to evaluate 
the effects of treatment with a 5-alpha reductase inhibitor (5ARI) on storage symptoms in patients with BPH.
Methods: This study was conducted in 738 patients with lower urinary tract symptoms secondary to BPH. Patients with a pros-
tate volume of higher than 30 mL on the transrectal ultrasound were classified into two groups: group A, in which an alpha block-
er was solely administered for at least 12 months, and group B, in which a combination treatment regimen of an alpha blocker 
plus 5ARI was used. This was followed by an analysis of the changes in parameters such as the total International Prostate Symp-
tom Score (IPSS), voiding symptom subscore, and storage symptom subscore between the two groups. In addition, we examined 
whether there was a significant difference between the two groups in the degree of change in storage symptoms between before 
and after the pharmacological treatment.
Results: Of the 738 men, 331 had a prostate volume ≥30 mL, including 150 patients in group A and 181 patients in group B. To-
tal IPSS, the voiding symptom subscore, and the storage symptom subscore were significantly lower after treatment than before 
treatment in both groups (P<0.05). A comparison of the degree of change between before and after treatment, however, showed 
no significant differences in the storage symptom subscore between the two groups (P>0.05).  
Conclusions: Alpha blocker and 5ARI combination treatment is effective for patients with BPH including storage symptoms. 
However, 5ARI does not exert a significant effect on storage symptoms in BPH patients.
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is a disease that causes 
bladder outlet obstruction (BOO) resulting from functional ob-
struction due to the adjustment of the nerves innervating the 
smooth muscle layer of the prostate gland and anatomical ob-
struction due to the increased size of the prostate gland. BPH is 
one of the main etiologic factors responsible for the occurrence 
of lower urinary tract symptoms (LUTS) in post-middle aged 
men [1]. The pharmacological treatments for BPH mainly in-
clude alpha blockers and 5-alpha reductase inhibitors (5ARIs). 
5ARI blocks the pathway through which testosterone is trans-
formed into dehydrotestosterone [2] and thereby suppresses the 
proliferation of interstitial cells and epithelial cells in the pros-
tate gland. It is also known to reduce the size of the prostate 
gland by apoptosis in the prostate gland tissue [3]. The LUTS of 
BPH, the severity of which is improved by these pharmacologi-
cal treatments, can be divided into voiding symptoms and stor-
age symptoms. The alpha blockers and 5ARIs that are currently 
available have focused on the alleviation of voiding symptoms. 
Of the LUTS, however, storage symptoms are more common 
than voiding symptoms [4] and are known to have a greater ef-
fect on quality of life (QoL) [5,6]. In the treatment of BPH, 
therefore, the effect on storage symptoms should be seriously 
considered. The storage symptoms that patients with BPH com-
plain of are closely associated with the detrusor muscle as a sec-
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ondary change due to the BOO [7]. Treatment agents for BPH 
alleviate this BOO and thereby improve the voiding symptoms. 
There is also a possibility, therefore, that they might have an ef-
fect on the storage symptoms. As a matter of fact, little is known 
about the exact pharmacological mechanisms. On the basis of 
various hypotheses, the effects of alpha blockers on storage 
symptoms have been reported, but to the effects of 5ARI have 
not yet been investigated. 
  The International Prostate Symptom Score (IPSS) is com-
monly used to assess the initial symptoms of patients with BPH, 
and changes in this score have been reported to be useful in as-
sessing the treatment response or the disease progression. We 
speculated that the IPSS would be a useful indicator for the cur-
rent study because it is divided into a voiding symptom subscore 
and a storage symptom subscore. 
  Given the above background, we attempted to examine the 
effect of 5ARI on storage symptoms in BPH patients. We com-
pared the difference in changes in storage symptoms between 
an alpha blocker monotherapy group and an alpha blocker+ 
5ARI combination therapy group with the use of the IPSS. 
MATERIALS AND METHODS
The current study was a single-center, retrospective analysis and 
it was approved by the institutional review board of our medi-
cal institution. The current study was conducted in 738 patients 
who visited the outpatient clinic with a chief complaint of LUTS 
during a period ranging from January 2008 to March 2009. All 
patients underwent tests such as urinalysis, prostate-specific 
antigen (PSA) measurement, maximal uroflow rate (Qmax), 
postvoid residual volume (PVR), transrectal ultrasonography 
(TRUS), and completion of the IPSS questionnaire.
  Patients with LUTS (IPSS ≥ 8 points) and treated with an al-
pha blocker (e.g., doxazosin, tamsulosin, terazosin, or alfuzo-
sin) and/or 5ARI (e.g., finasteride or dutasteride) for at least 12 
months and with a prostate volume of higher than 30 mL on 
the TRUS were enrolled. Exclusion criteria were patients who 
were diagnosed with prostate cancer following the test, who 
underwent transurethral resection of the prostate or other sur-
gical intervention related to BPH, who had neurogenic bladder, 
or who had a history of recurrent or complicated urinary tract 
infection or bladder stones. Enrolled patients were classified into 
two groups: group A, in which the alpha blocker was solely ad-
ministered for at least 12 months, and group B, in which a com-
bination treatment regimen of alpha blocker with 5ARI was 
used for at least 12 months. The patients took alpha blocker and 
5ARI from the beginning of treatment; the 5ARI was not added 
after alpha blocker monotherapy. This was followed by an anal-
ysis of the changes in parameters such as the total IPSS, voiding 
symptom subscore, storage symptom subscore, and QoL score 
between the two groups. In addition, we examined whether 
there was a significant difference between the two groups in the 
degree of change in storage symptoms between before and after 
the pharmacological treatment. Statistical analysis was per-
formed by using paired Student’s t-tests. All data were analyzed 
by using SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA). A value 
of P<0.05 was considered statistically significant. 
 
RESULTS
Of the 738 men, 331 (44.8%) had a prostate volume of ≥ 30 mL 
and had been treated with medication for at least 12 months. A 
total of 150 patients had been treated with an alpha blocker only 
(group A) and 181 patients had received combined medication 
with an alpha blocker and 5ARI (group B). The mean age of the 
patients was 62.4±0.82 years in group A and 67.08±0.60 years 
in group B. The prostate volume was 41.5±1.73 mL on average 
in group A and 48.1±1.38 mL on average in group B. Before 
treatment, there were no significant differences in Qmax, PSA, 
or PVR between the two groups (P>0.05). 
  Before treatment, the IPSS and voiding symptom subscore 
were 14.65±0.67 points and 8.42±0.46 points in group A, re-
spectively, and 16.46±0.67 points and 9.61±0.44 points in 
group B, respectively. This difference was not statistically signifi-
cant (P>0.05) (Table 1). After treatment, the IPSS and voiding 
symptom subscore were 12.16±0.68 points and 6.82±0.44 
points in group A (Fig. 1), respectively, and 13.77±0.69 points 
and 7.93±0.41 points in group B (Fig. 2), respectively. These re-
sults indicated that the IPSS and voiding symptom subscore 
were significantly lower after treatment than before treatment 
(P<0.05). In addition, before treatment, the storage symptom 
subscore was 6.23±0.31 points in group A and 6.84±0.31 points 
in group B. This difference was not statistically significant (P> 
0. 05). After treatment, it was found to be 5.34±0.29 points and 
5.83±0.31 points in groups A and B, respectively. These results 
indicate that the storage symptom subscore was significantly 
lower after treatment than before in both groups (P<0.05). 
  Before treatment, the QoL score was 3.47±0.10 points in 
group A and 3.71±0.09 points in group B. This difference was 
not statistically significant (P>0.05). After treatment, the QoL 154    www.einj.or.kr
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score was 2.90±0.11 points and 3.09±0.10 points in groups A 
and B, respectively. These results indicate that the QoL score was 
significantly lower after treatment than before in both groups 
(P<0.05). 
  The comparison of the degree of change between before and 
after treatment, however, showed that there were no significant 
differences in the storage symptom subscore between the two 
groups (P>0.05) (Fig. 3).
DISCUSSION
In the current study, the analysis of the baseline characteristics 
of the patients showed that mean age and mean prostate volume 
were relatively higher in group B than in group A. According to 
several BPH guidelines, combination therapy with an alpha 
blocker and 5ARI is more effective in patients with symptoms 
related to a large prostate volume; therefore, concomitant use of 
these treatment regimens has been recommended [8,9]. Ac-
cording to one study that examined the degree of use of combi-
nation therapy in an actual clinical setting, the use was propor-
tional to the size of prostate gland [10]. Concomitant use of the 
two treatment regimens is prescribed by physicians with a com-
plete understanding of the above rationale. It can therefore be 
inferred that the size of the prostate gland was slightly greater in 
the combination therapy group than in the monotherapy group. 
Table 1. Comparison of the baseline characteristics of the pa-
tients
Variables Group A Group B P-value
No. of patients 150 181
Age (yr) 62.40±0.82 67.08±0.60 0.001
Prostate volume (g) 41.50±1.73 48.10±1.38 0.007
Qmax (mL/sec) 12.73±0.65 11.95±0.40 0.549
PSA (ng/mL) 3.33±0.44 4.21±0.50 0.210
PVR (mL) 59.0±9.71 86.43±7.40 0.17
IPSS
Total 14.65±0.67 16.46±0.67 0.061
Storage subscore 6.23±0.31 6.84±0.31 0.172
Voiding subscore 8.42±0.46 9.61±0.44 0.066
QoL subscore 3.47±0.106 3.71±0.094 0.099
Values are presented as mean±SEM.
Qmax, maximum urinary flow rate; PSA, prostate specific antigen; 
PVR, post voiding residual volume; IPSS, International Prostate Symp-
tom Score ; QoL, quality of life.
Group A: alpha blocker group. Group B: alpha blocker + 5ARI group.
Fig. 1. Comparison of the total International Prostate Symptom 
Score (IPSS) and the storage and voiding subscores between be-
fore and after medication (month 12) in group A (alpha blocker 
group). 
a)P<0.05 compared with before medication.
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Fig. 2. Comparison of the total International Prostate Symptom 
Score (IPSS) and the storage and voiding subscores between be-
fore and after medication (month 12) in group B (alpha blocker 
+5-alpha reductase inhibitor group). 
a)P<0.05 compared with 
before medication. 
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Fig. 3. The mean change from baseline to 12 months in the total 
International Prostate Symptom Score (IPSS) and the voiding 
and storage subscores in group A (alpha blocker group) and 
group B (alpha blocker+5-alpha reductase inhibitor group).
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It is well established that the size of the prostate gland increases 
with age. This leads to the speculation that the mean age was 
higher in group B, in which the size of the prostate gland was 
relatively greater than in group A. It is also probable that the 
difference in these baseline characteristics of the patients might 
have affected the treatment outcomes. However, according to 
the measures indicative of the symptoms, such as the IPSS, 
Qmax, and PVR, there were no significant differences between 
the two groups. This implies that age and prostate volume were 
not significant pretreatment factors that affected the treatment 
outcomes. 
  The IPSS, which was used as an indicator of the treatment 
outcomes in the current study, has already been reported in oth-
er studies to have no relationship with prostate volume [11]. It 
is therefore presumed that the difference in the prostate volume 
might not have been a significant factor determining treatment 
outcomes. In the current study, the total IPSS, voiding symp-
tom subscore, and storage symptom subscore were significantly 
decreased after the drug treatments in both groups. Several 
studies have reported the effects of alpha blocker on storage 
symptoms. A long time ago, Lepor et al. [12] reported that the 
total IPSS, voiding symptom subscore, and storage symptom 
subscore were significantly decreased after the use of terazosin. 
Recent studies have examined naftopidil, an alpha 1A/D adre-
noceptor blocker, and showed that the voiding symptom sub-
score and storage symptom subscore were significantly decreased 
after monotherapy with naftopidil. In addition, after the mono-
therapy with naftopidil, the symptoms of nocturia were also 
improved in patients with BPH who concurrently had noctur-
nal polyuria [13]. Furthermore, according to a study using silo-
dosin, an alpha 1A adrenoceptor selective antagonist, the total 
IPSS and storage and voiding symptom subscores were signifi-
cantly decreased, the maximum cystometric capacity was sig-
nificantly increased, and the detrusor overactivity was lost and 
then improved. These findings were also demonstrated in the 
urodynamic study [14]. 
  Little is known about the exact mechanisms by which alpha 
blockers affect storage symptoms. Nevertheless, the following 
hypotheses exist: an alpha 1D receptor is involved in the regula-
tion of the detrusor overactivity, because it is mainly distributed 
in the bladder detrusor muscle, and the micturition reflex is 
suppressed owing to the blockage of alpha 1D receptor, which 
is distributed in the spinal cord nerve system. Moreover, animal 
experiments have demonstrated that an alpha 1A receptor is in-
volved in the c-fiber afferent activity. This hypothesis led to the 
reports showing that alpha blockers improve the storage symp-
tom in patients with BPH [15,16]. Another hypothesis is that 
the bladder outlet resistance is decreased if the size of the en-
larged prostate, which mechanically obstructs the bladder out-
let, is decreased in patients with BPH, thus leading to an im-
provement in storage symptoms. On the basis of this concept, 
Becher et al. [17] reported that storage symptoms were im-
proved with the use of dutasteride, a type of 5 ARI, alone, and 
that in the dutasteride and tamsulosin combination treatment 
group, as compared with the monotherapy group, the storage 
and voiding subscores were significantly decreased. In addition, 
the voiding subscore was further decreased.  
  In another study, an analysis was performed mainly to evalu-
ate the effects on storage symptoms of a concomitant treatment 
regimen of finasteride with alpha blocker. That study showed 
effects of a markedly higher degree in improving the symptoms 
in patients with severe storage symptoms [18]. We investigated 
the effect in BPH patients of medical treatment of more than 12 
months. Reduction of prostate volume by 5ARI was noted from 
3 months markedly and was sustained for 12 months, but the 
degree of reduction after 1 year was not significant [19]. In the 
current study, as shown in other studies, a comparison was made 
between the combination therapy group and the monotherapy 
group. Through a comparative analysis of whether there was a 
significant difference in the degree of improvement in symp-
toms between the two groups from the perspective of storage 
symptoms, the effect of 5ARI on storage symptoms was con-
firmed. In the current study, there were also effects in improv-
ing the storage symptoms in the combination therapy group. In 
the comparison of the degree of the improvement in the storage 
symptoms between the monotherapy group and the combina-
tion therapy group, however, no significant differences were 
found. These results lead us to speculate that 5ARI has an equiv-
alent profile or a lower degree of effect on the storage symptoms 
as compared with alpha blocker. This might be because although 
5ARI improves the BOO in a manner similar to that of alpha 
blocker, the mechanism may be one of the major mechanisms 
by which alpha blocker improves storage symptoms, such as the 
inhibition of the micturition reflex in the bladder or spinal cord. 
This suggests that although 5ARI is clinically useful from the 
perspective of voiding symptoms because it improves the inci-
dence of acute urinary retention, BPH-related surgery, and the 
peak urinary flow rate, it might not be of great help in improv-
ing storage symptoms. It can therefore be inferred that the ad-
ditional use of 5ARI might not be of further help in patients who 156    www.einj.or.kr
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complain of a persistent presence of storage symptoms and 
have a past history of taking an alpha blocker. Thus, additional 
methods by which the storage symptoms can be actively treated 
should be considered. 
  Although patients were not additionally given anticholiner-
gics in the current study, several studies have reported that a 
combination treatment regimen of alpha blocker with anticho-
linergics has a sufficient degree of effect on storage symptoms 
and produces no side effects in patients with BPH [20,21]. It 
can therefore be concluded that concomitant treatment with 
other drugs such as anticholinergics should be considered. Ad-
ditionally, the IPSS used in the current study has been demon-
strated to be effective in evaluating the treatment response. To 
clarify this more objectively, however, objective test regimens 
such as an urodynamic study should be performed in patients 
who complain of storage symptoms and in whom 5ARI was 
solely administered. 
  Another limitation of our study is that we did not analyze the 
difference by severity of storage symptoms. In the CombAT 
study [22], the mean IPSS storage subscores at baseline were 7.3 
and 7.2 in the tamsulosin groups, and storage symptoms im-
proved significantly in the patients who received combination 
therapy compared with monotherapy. In our study, the mean 
IPSS storage subscores at baseline were 6.84 in the combination 
therapy group and 6.23 in the alpha blocker therapy group. Thus, 
the mean IPSS storage subscores at baseline were less in our 
study than in the CombAT study. A difference in treatment re-
sults by severity of storage symptoms might have existed, and 
we should consider this aspect in the future. 
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